Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Does This Mutation Affect DLBCL Outcomes?

Biol Blood Marrow Transplant; ePub 2017 Aug 25; Lee, et al

Publish date:: August 30, 2017

MyD88 L265P mutation does not appear to impact post-ASCT progression-free or overall survival in patients with diffuse large B cell lymphoma (DLBCL), according to a retrospective analysis involving 165 individuals. Participants had DLBCL, underwent autologous stem cell transplantation (ASCT) at a single institution, and were followed for up to 20 years. Among the results:

MyD88 mutation status did not correlate with overall survival, post-ASCT overall survival, or progression-free survival.
Patients with non-germinal center B cell like subtype had significantly worse overall survival from initial diagnosis and after ASCT.

The authors noted that the International Prognostic Index remains the most reliable prognostic tool for patients with DLBCL undergoing ASCT.

Citation:

Lee Y, Liu J, Fricano K, et al. Lack of prognostic impact of MyD88 L265P mutation for DLBCL patients undergoing autologous stem cell transplantation. [Published online ahead of print August 25, 2017]. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2017.08.022.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Aggressive Lymphomas

Study Halted; ‘Hyperprogression’ Seen With Nivolumab for R/R PTCL,

CAR T-Cell Therapy Found Safe, Effective For HIV-Associated Lymphoma,

Bispecific CAR T-cell Therapy Yields Complete Responses in Relapsed/Refractory non-Hodgkin Lymphomas,

5F9 Plus Rituximab Take a Bite Out of Drug-Resistant NHL,

‘Encouraging’ Responses Seen With Durvalumab Plus R-CHOP in DLBCL,